Related Experiment Video
Updated: Jul 12, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a
Kang Le1, Jordan Vollenweider1, JingJing Han2
1Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University, GW Cancer Center, Washington, District of Columbia, USA.
Abstract:
Peripheral T-cell lymphoma (PTCL) is a clinically heterogeneous group that represents 10%-15% of all lymphomas. Despite improved genetic and molecular understanding, treatment outcomes for PTCL have not shown significant improvement. Although Janus kinase-2 (JAK2) plays an important role in myeloproliferative neoplasms, the critical role of JAK isoforms in mediating prosurvival signaling in PTCL cells is not well defined. Immunohistochemical analysis of PTCL tumors (n = 96) revealed high levels of constitutively active JAK3 (pJAK3) that significantly (p < 0.04) correlated with the activation state of its canonical substrate STAT3. Furthermore, constitutive activation of JAK3 and STAT3 positively correlated, at least in part, with an oncogenic tyrosine phosphatase PTPN11. Pharmacological inhibition of JAK3 but not JAK1/JAK2 significantly (p < 0.001) decreased PTCL proliferation, survival and STAT3 activation. A sharp contrast was observed in the pJAK3 positivity between ALK+ (85.7%) versus ALK-negative (10.0%) in human PTCL tumors and PTCL cell lines. Moreover, JAK3 and ALK reciprocally interacted in PTCL cells, forming a complex to possibly regulate STAT3 signaling. Finally, combined inhibition of JAK3 (by WHI-P154) and ALK (by crizotinib or alectinib) significantly (p < 0.01) decreased the survival of PTCL cells as compared to either agent alone by inhibiting STAT3 downstream signaling. Collectively, our findings establish that JAK3 is a therapeutic target for a subset of PTCL, and provide rationale for the clinical evaluation of JAK3 inhibitors combined with ALK-targeted therapy in PTCL.
Insights
Janus kinase-3 (JAK3) is a therapeutic target in Peripheral T-cell lymphoma (PTCL). Inhibiting JAK3, especially combined with ALK-targeted therapy, significantly reduces PTCL cell survival by blocking STAT3 signaling.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Peripheral T-cell lymphoma (PTCL) is a diverse group of lymphomas with poor treatment outcomes.
- The role of Janus kinase (JAK) isoforms in PTCL cell survival signaling remains unclear.
- Understanding the molecular drivers of PTCL is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the role of JAK isoforms, particularly JAK3, in PTCL cell signaling and survival.
- To determine if JAK3 is a viable therapeutic target in PTCL.
- To explore the potential of combining JAK3 inhibitors with ALK-targeted therapies.
Main Methods:
- Immunohistochemical analysis of PTCL tumors (n=96) to assess JAK3 and STAT3 activation.
- Pharmacological inhibition of JAK isoforms (JAK1, JAK2, JAK3) in PTCL cells.
- Investigating the interaction between JAK3 and ALK in PTCL cells.
- Evaluating the combined efficacy of JAK3 and ALK inhibitors on PTCL cell survival.
Main Results:
- High levels of constitutively active JAK3 (pJAK3) were found in PTCL tumors, correlating with STAT3 activation.
- Pharmacological inhibition of JAK3, but not JAK1/JAK2, significantly reduced PTCL proliferation, survival, and STAT3 activation.
- JAK3 activation was significantly higher in ALK-positive PTCL compared to ALK-negative PTCL.
- JAK3 and ALK were found to form a complex in PTCL cells, potentially regulating STAT3 signaling.
- Combined inhibition of JAK3 and ALK significantly decreased PTCL cell survival more than individual agents.
Conclusions:
- JAK3 is constitutively active and plays a critical role in PTCL cell survival signaling.
- JAK3 is a potential therapeutic target for a subset of PTCL patients.
- Combination therapy with JAK3 inhibitors and ALK-targeted agents warrants clinical evaluation for PTCL treatment.
More Related Videos
07:12Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:22PI3K/mTOR/AKT Signaling Pathway
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:41Non-Canonical Wnt Signaling Pathways
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...